Skip to content
Head to head

BioCryst Pharmaceuticals vs Takeda Pharmaceutical

Side-by-side on the measures that matter, with a plain-English read. Full detail: BCRX · TAK

Updated 10 minutes ago

1-year performance, rebased to 100

BCRX +2.7%TAK +56.6%
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical has the highest Quant Rating (90); Takeda Pharmaceutical has done best over the past year (+57%); Takeda Pharmaceutical pays the highest dividend yield.
BCRXTAK
Snapshot
SectorDrug Manufacturers - Specialty & Generic--
Last price7.2221.77
Change today-1.37%+1.68%
1-year return+2.7%+57.5%
Market cap$1.86B$69.76B
52-week range6.23 – 11.2213.92 – 22.07
Valuation
P/E (TTM)-5.64311.00
P/E percentile, own 5-yr range70th100th
P/B-4.681.50
Dividend yield0.00%1.44%
Profitability & growth
EPS (TTM)1.21-0.30
Net profit (TTM)$311.33M$-970.94M
Revenue (TTM)$961.51M$4.69T
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+13.1%+6.7%
Gross margin97.9%65.8%
Operating margin42.5%14.3%
Net margin-37.4%0.9%
Free cash flow (TTM)$365.85M$433.95B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership104.1%51.3%
Insider activity (12mo)38 buy / 9 sell19 buy / 31 sell
Short interest (% of float)10.8%0.1%
Analyst consensus67% buy / 33% hold (6)100% buy (1)
Analyst price target$17 (+135%)$50 (+132%)
StockVane view
StockVane Quant RatingD (45)C (90)
Company
Employees43547,029
Founded19861781

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.